Bioreductive Activation

Bioreductive Activation is a prodrug activation mechanism in which enzymatic reduction under hypoxic or low-redox conditions selectively converts an inactive prodrug into its active cytotoxic form, distinguishing it from other activation mechanisms by its reliance on cellular reductases and oxygen-sensitive biotransformation.

87

Publications

6.2K

Citations

403

Authors

125

Institutions

Publications per year

2017–2026

8

Authors

403

  1. WR
    William R. Wilson

    University of Auckland, New Zealand

    7 publications · 438 citations

    7

    h-index

  2. RM
    Roger M. Phillips

    University of Bradford, United Kingdom

    7 publications · 235 citations

    7

    h-index

  3. WA
    William A. Denny

    University of Auckland, New Zealand

    7 publications · 317 citations

    7

    h-index

  4. DR
    David Ross

    University of Colorado Health, United States

    6 publications · 567 citations

    6

    h-index

  5. DS
    David Siegel

    University of Colorado Health, United States

    5 publications · 514 citations

    5

    h-index

1–5 of 403

Venues

  1. PubMed

    Repository · 18 publications · 1.1K citations

    16

    h-index

  2. Journal of Medicinal Chemistry

    7 publications · 1.1K citations

    7

    h-index

  3. British Journal of Cancer

    BJC · 5 publications · 261 citations

    5

    h-index

  4. Journal of the American Chemical Society

    JACS · 3 publications · 215 citations

    3

    h-index

  5. Biochemical Pharmacology

    3 publications · 154 citations

    3

    h-index

1–5